Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,050.00
Bid: 12,038.00
Ask: 12,040.00
Change: -106.00 (-0.87%)
Spread: 2.00 (0.017%)
Open: 12,092.00
High: 12,178.00
Low: 12,010.00
Prev. Close: 12,156.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

REFILE-After 4.2 million COVID-19 cases in November, U.S. pins hope on vaccine

Tue, 01st Dec 2020 15:10

(Deletes extraneous "refuse to" in 2nd paragraph)

WASHINGTON, Dec 1 (Reuters) - The United States entered the
final month of the year hoping that promising vaccine candidates
will soon be approved to halt the rapidly spreading novel
coronavirus after 4.2 million new cases were reported in
November.

The new COVID-19 cases were more than double the previous
monthly record set in October, as large numbers of Americans
still refuse to wear masks and continue to gather in holiday
crowds, against the recommendation of experts.

With outgoing President Donald Trump's coronavirus strategy
relying heavily on a vaccine, a Food and Drug Administration
panel of outside advisers will meet on Dec. 10 to discuss
whether to recommend the FDA authorize emergency use of a
vaccine developed by Pfizer Inc.

A second candidate from Moderna Inc could follow a
week later, officials have said, raising hopes that Americans
could start receiving inoculations before the end of the year,
although widespread vaccinations could take months.

Other global pharmaceuticals including AstraZeneca PLC
and Johnson & Johnson also have vaccines in the
works, leading a member of the Trump administration's "Operation
Warp Speed" program to predict the country could be vaccinated
by June.

"One hundred percent of the Americans that want the vaccine
will have the vaccine by (June). We will have over 300 million
doses available to the American public well before then," Paul
Ostrowski, the vaccine program's director of supply, production
and distribution, told MSNBC television on Monday.

In the meantime, leading health officials are pleading with
Americans to follow their recommendations and help arrest a
pandemic that killed more than 36,000 people in November,
pushing hospitalizations to a record high of nearly 93,000 on
Sunday, according to a Reuters tally.

The widespread impact of the pandemic has led
Merriam-Webster to choose "pandemic" as the Word of the Year
after it racked up the most online dictionary lookups of any
word.

"Sometimes a single word defines an era, and it's fitting
that in this exceptional - and exceptionally difficult - year, a
single word came immediately to the fore," the dictionary
publisher said.

With more than 10,000 people dying and 1.1 million
contracting the novel coronavirus in the week ended Sunday,
Trump has remained focused on overturning the results of the
Nov. 3 election won by President-elect Joe Biden, denying Trump
a second term.

Biden has pledged to make combating the coronavirus his top
priority upon taking office on Jan. 20, saying he will rely on
the best scientific evidence.

In the absence of a federal blueprint to curb the spread of
the virus, states are issuing new or revamped restrictions on
businesses and social life.

California's governor said he may renew a stay-at-home order
in the coming days, warning that ICU admissions are on track to
exceed statewide capacity by mid-December unless public health
policies and social behavior change.

"The red flags are flying," Governor Gavin Newsom told
reporters in an online briefing. "If these trends continue,
we're going to have to take much more dramatic, arguably
drastic, action."

(Reporting by Reuters staff; Writing by Daniel Trotta; Editing
by Bernadette Baum)

More News
11 Apr 2024 17:13

FTSE 100 edges lower as financials drag

Lok'nStore surges to all-time high after buyout by Shurgard

*

Read more
11 Apr 2024 17:07

Banks weigh down Europe's STOXX 600 after ECB signals rate cuts

Outlook hike sends Ambu shares up

*

Read more
11 Apr 2024 15:56

London close: Stocks finish lower as ECB stands pat

(Sharecast News) - London's stock markets finished in negative territory on Thursday, as investors reacted to the European Central Bank's latest policy announcement and a producer price index release in the United States.

Read more
11 Apr 2024 11:50

LONDON MARKET MIDDAY: Europe takes hit on nerves ahead of ECB decision

(Alliance News) - European equities sunk lower at midday on Thursday, with sentiment hurt by hotter-than-expected inflation from the US crushing hopes of interest rate cuts.

Read more
11 Apr 2024 08:56

TOP NEWS: Astra plans 7% dividend hike for 2024 after no rise in 2023

(Alliance News) - AstraZeneca PLC said it intends to raise its annualised dividend for 2024, citing confidence in its business performance and cash generation.

Read more
11 Apr 2024 08:54

LONDON MARKET OPEN: European markets mixed ahead of ECB decision

(Alliance News) - European equities lacked direction early Thursday morning, ahead of an interest rate decision from the European Central Bank this afternoon.

Read more
11 Apr 2024 07:49

LONDON BRIEFING: Astra promises dividend hike; Darktrace ups guidance

(Alliance News) - Stocks in London are called to open slightly higher on Thursday, as investors eye the latest interest rate decision from the European Central Bank, a day after a hotter-than-expected US inflation reading.

Read more
11 Apr 2024 07:20

AstraZeneca to hike 2024 dividend by 7%

(Sharecast News) - Biopharma giant AstraZeneca has announced that it will increase its annual dividend by 7%, which the board said demonstrates its confidence in the company's performance and cash generation.

Read more
8 Apr 2024 08:36

TOP NEWS: AstraZeneca hails neurological data for Ultomiris, Soliris

(Alliance News) - AstraZeneca PLC on Monday said long-term data in generalised myasthenia gravis will underscore the "vital role" of its Ultomiris and Soliris antibodies in the treatment landscape.

Read more
8 Apr 2024 07:43

LONDON BRIEFING: Astra hails neurology data; CVS flags cyberattack

(Alliance News) - London's FTSE 100 is called to open a touch higher on Monday, ahead of an interest rate decision in the eurozone and a US inflation reading later in the week.

Read more
8 Apr 2024 07:02

AstraZeneca's Enhurtu cancer gets US green light for adult patients

(Sharecast News) - AstraZeneca and Daiichi Sankyo's Enhertu cancer drug has been approved in the US for adult patients with unresectable or metastatic solid tumours who have received prior systemic treatment and have no satisfactory alternative options.

Read more
8 Apr 2024 06:53

TOP NEWS: AstraZeneca's, Daiichi's Enhertu receives US FDA approval

(Alliance News) - AstraZeneca PLC and Daiichi Sankyo Co Ltd on Saturday announced that the US Food & Drug Administration has approved their cancer drug conjugate for patients with metastatic HER2-positive solid tumours.

Read more
5 Apr 2024 09:42

AstraZeneca makes "breakthrough" in treating small cell lung cancer

(Alliance News) - AstraZeneca PLC on Friday reported positive results relating to its Imfinzi cancer treatment in phase III trials.

Read more
5 Apr 2024 07:50

LONDON BRIEFING: Shell to book USD600 million first-quarter write-off

(Alliance News) - London's FTSE 100 is called to open lower on Friday, with hawkish remarks from Federal Reserve policymakers and fears of ratcheting Middle East tensions giving investors little to cheer about ahead of the latest US jobs data.

Read more
5 Apr 2024 07:23

AstraZeneca announces positive lung cancer treatment trial results

(Sharecast News) - AstraZeneca announced positive high-level results from a phase three trial demonstrating significant advancements in the treatment of limited-stage small cell lung cancer (LS-SCLC) on Friday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.